Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A reverse split, while on average a sign of bad news (typically delist avoidance), I believe could play well with this stock. The stock has a fairly high cap and has been fairly consistent on it's own at the $1 price range with lack of press. All depends on how they frame it with news and uplist visibility. Not like it would change the ownership percentages. Something I'm missing?
Reverse split
Have any near-term predictions?
I think he meant literally a few (3), and the "balast" reference was meant to be "ballast point"... the brewery he will buy his celebration beer from.
:)
Can't guess when the company is going to actually keep going up or just a run. Do not plan to sell personally if targets are still being met, as most profits are made by those who ride the longest with these long potential stocks.
This company doesn’t care about the OTC, primary focus seems to be on institutional investors and post-uplist. All I believe we will get is financial results, board announcements, and finally uplist info until we move to the next leg.
This has become my largest OTC holding with just over 50k shares, and here are the timelines/expectations that I will continue to hold until missed (without reasonable exp., and all hopefully exceeded):
February: Quarterly results posted with continued current portfolio growth
March-April: $2 per share, some level of news over board or uplist
June-July: $4 per share, Solid annual results statement & published on-time per SEC guidelines. Uplist news/timeline.
August-September: Uplist
October: ???
November-Beyond: Profit.
Has anyone visited their HQ/lab and can share contact or details? Going to be in the area in the next couple weeks and would love to check out the site. Sent an email via investor relations, have not heard anything.
Agree... don't want to sell prematurely and miss dramatic uplist bump. Seems like endgame time for pink sheets.
Maybe, news would have to be imminent.
Don't let it run yet, I need to buy more.
Agree, seems very likely. Good for me though, increased position again today.
Anything is possible if you believe. Let's go $10.
Throwing a few more shares into the hat tomorrow. Happy with performance.
Yes, depends on what their true uplist timing is and how portfolio performs/is marketed. Uplist is supposed to be short term per conferences, would not imagine later than June... should start seeing major media in a couple months to support if still target (would love to see more board members like Sorrentino). My estimate is ~$10 at uplist with a run following toward end of CY to upwards of $50 if executed well and product portfolio is what it seems.
Previous bumps didnt make sense given lack of media releases (hence why I initially started as a short positiom)... but could see that changing with the next one.. careful shorts (Ian).
Was not talking fiscal quarter. Expect good results from Q1 2019, which I would expect details to be shared ahead of filing given uplist desire.
And we can always cherry pick executive profiles and failed ventures, but does not mean there is a correlation. Einstein got a few things wrong, doesn't mean his entire works were as well. Let's talk about this ticker specifically and hear your concerns.
Remind us in a few months after we see first quarter results and any press releases.
Quite frankly, I don't think they are in a position to care too much about stock performance nor our gains (smaller fish). Once they're ready to uplist they'll start pumping out info in preparation.
Been buying consistently the past few months while low (currently at 40k shares).. so not upset about performance given confidence in long.
Expect this stock to skyrocket once we see sales results from the Endo products (Q1 '19).
I'm not minding the dip... buying all the way down. :)
Conference didn't give out too much more info... PRED better release something big soon if they want to have a shot to uplist near-term.
All that does is remove reporting obligation. There is no reason they can't still submit to EDGAR any filing for SEC acceptabce/publishing.
They can and have, but are not obligated to. Thought the 10k would have been posted, still may come Monday morning post acceptance. Ultimately they have audited financials, just depends on if their "big" investors desire it I guess.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001382943&owner=exclude&count=40
Value is not in current product line (although that on a monthly basis is becoming profitable).
OTC is not an SEC regulated exchange, but would still expect them to file based upon desire to uplist.
We'll see... could be submitted, depends on the backlog for processing before we see it. If filed, should see published no later than 10:30 EST.
The next week will be fun... with publishing of a potential 10-K, investor conferences, latest news releases...
Hope my next funds transfer fast enough.
Public float would need to be larger to be a 75 day req. ($75MM-$700MM, assume they aren't there yet). Should see them post within the 90 days... if they plan to...
But I would love to see it tomorrow. :) Would help them stay at a high PPC for that NASDAQ list.
Form 10-k should be published by 9/28 if they are planning on doing it. (End of FY+90).
Regardless of whether it keeps going up.. Congrats on the gain georgie/all who decided to sell.
Note: I'm still in on a long.
Tough to compare.. not apples to apples. They have since released audit details, and included quarterly financials in the presentation.
No major deviations from the material posted. Good sales results, and time is growing very close for their major endometriosis items to hit market.
Toxic to short sellers? Yep.
Presentation for tomorrow was posted on the IR page.
http://predtechgroup.com/wp-content/uploads/2018/09/PRED-Investor-Presentation-090318_Final.pdf
Will be tough to get a straight answer on here as nearly everyone is invested either from a short or buy standpoint. But I've gone both ways, shorted the stock previously early this year and now bought a few thousand shares that I'm holding on to.
I'm expecting either something at the conference or shortly after. Based upon what I've seen with OTCs, the ones that are most successful are the ones that pose themselves to investors before they reveal too much... as they want to have the big dogs jump in pre-hike/volatility.
Honestly though, if I don't see anything bu November, I'll probably remove my position and move on.
In the words of NSYNC... Buy Buy Buy
Everyone needs to get over the float. A high float is what is needed for large investors to enter into the game given where this company is at.
October 15th?
No news?.... This seems substantial:
NOTE 14 RELIANCE ON THIRD PARTY VALUATIONS
The Company has relied on third party valuations to determine if an impairment should be recorded and
other purposes as of March 31, 2018.
Equity Method Investments – Lifecode Genetics, Inc.
The third-party valuator, using cash flow projections under various assumptions and after considering
discounts for marketability and minority interests, concluded the fair market value of Juneau
Biosciences, LLC to be approximately $1,320,000,000. At March 31, 2018 the Company (including
affiliates) owned approximately 49% of Juneau (See note 7), which would value this investment at
approximately $646,800,000.
PREDICTIVE TECHNOLOGY GROUP, INC.
- 24 -
Trade Secrets – Predictive Biotech, Inc.
The third-party valuator, using cash flow projections under various assumptions and after considering
discounts for venture capital, concluded the fair market value of trade secrets acquired with Renovo to
be approximately $501,000,000.
Other Patents and Technologies – Patents regarding Degenerative Disc Disease
Patents were acquired by the issuance of Predictive Therapeutics Class A units as described in note 6.
The third-party valuator, using cash flow projections under various assumptions and after considering
discounts for venture capital, concluded the fair market value of such patents acquired to be
approximately $246,000,000.